// App-Quantinova.ai

: Circulating Tumor DNA As a Biomarker for Molecular Residual Disease Assessment in Patients with Diffuse Large B-Cell Lymphoma

Researchers

Presenter

  • Mayur Narkhede

Principal Investigators

  • Sarah Tomassetti

  • Madiha Iqbal

  • Katie LaBarbera

  • Hayley Widden

  • Ryan Benrud

  • Richa Rathore

  • Ekaterina Kalashnikova

  • Allyson Koyen Malashevich

  • Minetta Liu

  • Alexey Aleshin

Medical Centers

  • Division of Hematology / Oncology, Department of Internal Medicine, Harbor-UCLA Medical Center and The David Geffen School of Medicine at UCLA, Torrance, CA, CA

  • Mayo Clinic, Division of Hematology-Oncology and Blood and Marrow Transplantation Program, Jacksonville, FL

  • The Lundquist Research Institute, Torrance, CA

  • Division of Hematology/Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Diffuse large B-cell lymphoma

Biomarkers

  • Proliferation marker protein Ki-67

  • Circulating DNA

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Multinational

  • Feasibility

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved